잠시만 기다려 주세요. 로딩중입니다.

A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy

대한간암학회지 2019년 19권 1호 p.74 ~ 78
황상연, 이선미, 임정우, 전기정, 최철원, 김경수, Jeon Wan,
소속 상세정보
황상연 ( Hwang Sang-Youn ) - Dongnam Institute of Radiological & Medical Sciences Department of Internal Medicine
이선미 ( Lee Seon-Mi ) - Dongnam Institute of Radiological & Medical Sciences Department of Internal Medicine
임정우 ( Im Jung-Woo ) - Dongnam Institute of Radiological & Medical Sciences Department of Internal Medicine
전기정 ( Jeon Ki-Jeong ) - Dongnam Institute of Radiological & Medical Sciences Department of Internal Medicine
최철원 ( Choi Cheol-Won ) - Dongnam Institute of Radiological & Medical Sciences Department of Radiation Oncology
김경수 ( Kim Kyung-Su ) - Dongnam Institute of Radiological & Medical Sciences Department of Radiation Oncology
 ( Jeon Wan ) - Dongnam Institute of Radiological & Medical Sciences Department of Radiation Oncology

Abstract


Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a firstline treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy.

키워드

Hepatocellular carcinoma; Sorafenib; Nivolumab

원문 및 링크아웃 정보

 

등재저널 정보